Publications by authors named "Joanna Roder"

Claim this Profile
D
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel.
Minu K Srivastava, Wei Zou, Mark McCleland, Joanna Roder, Senait Asmellash, Heinrich Roder

J Immunother Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance.
Matthew A Koc, Timothy Aaron Wiles, Daniel C Weinhold, Steven Rightmyer, Amanda L Weaver, Joanna Roder, Heinrich Roder

J Mass Spectrom Adv Clin Lab· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semi-Quantitative MALDI Measurements of Blood-Based Samples for Molecular Diagnostics.
Matthew A Koc, Senait Asmellash, Patrick Norman, Steven Rightmyer, Joanna Roder, Heinrich Roder

Molecules· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting prognosis in COVID-19 patients using machine learning and readily available clinical data.
Thomas W Campbell, Melissa P Wilson, Heinrich Roder, Samantha MaWhinney, Robert W Georgantas, Joanna Roder

Int J Med Inform· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Explaining multivariate molecular diagnostic tests via Shapley values.
Joanna Roder, Laura Maguire, Robert Georgantas, Heinrich Roder

BMC Med Inform Decis Mak· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test.
Devalingam Mahalingam, Leonidas Chelis, Imran Nizamuddin, Sunyoung S Lee, Stylianos Kakolyris, Heinrich Roder, Joanna Roder

Cancers (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Peter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, Alexander Rosemurgy, Sharona B Ross, Heinrich Roder, Joanna Roder

J Pancreat Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proposal for score assignment to characterize biological processes from mass spectral analysis of serum.
Joanna Roder, Lelia Net, Carlos Oliveira, Krista Meyer, Senait Asmellash, Heinrich Roder

Clin Mass Spectrom· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors.
Mirte Muller, Karlijn Hummelink, Daan P Hurkmans, Anna-Larissa N Niemeijer, Kim Monkhorst, Joanna Roder, Heinrich Roder

Clin Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer.
Sabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, Sven Mahner, Ignace Vergote, Heinrich Roder

Cancers (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach.
Julia Grigorieva, Senait Asmellash, Lelia Net, Maxim Tsypin, Heinrich Roder, Joanna Roder

Int J Mol Sci· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Consuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, Brian Schwartz, Sergey Orlov, Joanna Roder

Oncologist· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data.
Joanna Roder, Carlos Oliveira, Lelia Net, Maxim Tsypin, Benjamin Linstid, Heinrich Roder

BMC Bioinformatics· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the power of gene set enrichment analyses.
Joanna Roder, Benjamin Linstid, Carlos Oliveira

BMC Bioinformatics· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust identification of molecular phenotypes using semi-supervised learning.
Heinrich Roder, Carlos Oliveira, Lelia Net, Benjamin Linstid, Maxim Tsypin, Joanna Roder

BMC Bioinformatics· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Paolo A Ascierto, Mariaelena Capone, Antonio M Grimaldi, Domenico Mallardo, Ester Simeone, Heinrich Roder, Joanna Roder

J Immunother Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Francesco Grossi, Carlo Genova, Erika Rijavec, Giulia Barletta, Federica Biello, Joanna Roder, Heinrich Roder

Lung Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
Mary Jo Fidler, Cristina L Fhied, Joanna Roder, Sanjib Basu, Selina Sayidine

BMC Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.
Jeffrey S Weber, Mario Sznol, Ryan J Sullivan, Shauna Blackmon, Genevieve Boland, Joanna Roder, Heinrich Roder

Cancer Immunol Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Vanesa Gregorc, Silvia Novello, Chiara Lazzari, Sandro Barni, Michele Aieta, Joanna Roder, Heinrich Roder

Lancet Oncol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Thomas E Stinchcombe, Joanna Roder, Amy H Peterman, Julia Grigorieva, Carrie B Lee

J Thorac Oncol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, Solange Peters, Heinrich Roder, Joanna Roder

Lung Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
David P Carbone, Keyue Ding, Heinrich Roder, Julia Grigorieva, Joanna Roder

J Thorac Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In situ mass spectrometry of autoimmune liver diseases.
Christopher L Bowlus, Erin H Seeley, Joanna Roder, Julia Grigorieva, Heinrich Roder

Cell Mol Immunol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Christine H Chung, Erin H Seeley, Heinrich Roder, Julia Grigorieva, Maxim Tsypin, Joanna Roder

Cancer Epidemiol Biomarkers Prev· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis